Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis” [J Hepatol 71 (2019) 543–552](S0168827819303009)(10.1016/j.jhep.2019.05.014)

Yau T.CHIUN HSUKim T.-Y.Choo S.-P.Kang Y.-K.Hou M.-M.Numata K.Yeo W.Chopra A.Ikeda M.Kuromatsu R.Moriguchi M.Chao Y.Zhao H.Anderson J.Dela Cruz C.Kudo M.2022-08-192022-08-1920190168-8278https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074524779&doi=10.1016%2fj.jhep.2019.09.013&partnerID=40&md5=891c5841375ad25f047d18546a3db432https://scholars.lib.ntu.edu.tw/handle/123456789/617116Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis” [J Hepatol 71 (2019) 543–552](S0168827819303009)(10.1016/j.jhep.2019.05.014)corrigendum10.1016/j.jhep.2019.09.013316686712-s2.0-85074524779